Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 401–500 of 1,002
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 81
Self-citationAntiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“Meanwhile, antiangiogenic therapy reduces the levels of immunosuppressive TIICs including Tregs and MDSCs in peripheral blood, accompanied by an improvement in the Th1 cell response [99].”
BackgroundInfluentialSelf-citationNanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 78
Chemokines and chemokine receptors: Update on utility and challenges for the clinician
Roy, I., Evans, D. B., & Dwinell, M. B. (2014) · Surgery · doi:10.1016/j.surg.2014.02.006 · Cited by 87
Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation
Togashi, Y., & Nishikawa, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_58 · Cited by 85
“…oral and ovarian cancer; CCR10 with CCL28 and CXCR4 with CXCL12 in ovarian cancer; and CCR5 with CCL5 in pancreatic cancer, etc.) (Curiel et al. 2004; Ishida et al. 2006; Wei et al. 2007; Gobert et al. 2009; Tan et al. 2009; Watanabe et al. 2010; Facciabene et al. 2011; Svensson et al. 2012).”
BackgroundAre BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 80
“These new vessels, however, rarely rescue the deficits associated with the limitations of oxygen diffusion,(57) and hypoxia has been shown to increase recruitment of TREG through the CCL28CCR10 axis.(58,59) Moreover, there is overwhelming evidence supporting the hypoxia-induced secretion of inhibitory molecules and th…”
BackgroundImmunomodulation of Tumor Vessels: It Takes Two to Tango
Johansson-Percival, A., He, B., & Ganss, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.08.001 · Cited by 73
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 84
“Examples of tumor-extrinsic mechanisms include activation of immunosuppressive immune and stromal cell populations such as myeloid derived suppressor cells (MDSCs), M2-like macrophages, immature DCs, regulatory T cells (Tregs) and cancer associated potentially in the form of anti-TGF-β , anti-VEGFA or anti-VEGFR antib…”
BackgroundInfluentialTargeting macrophages: a novel treatment strategy in solid tumors
Liu, M., Liu, L., Song, Y., Li, W., & Xu, L. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03813-w · Cited by 77
The influence of endothelial metabolic reprogramming on the tumor microenvironment
Kane, K. M., Edwards, D. N., & Chen, J. (2024) · Oncogene · doi:10.1038/s41388-024-03228-5 · Cited by 88
Triner, D., Xue, X., Schwartz, A. J., Jung, I., Colacino, J. A., & Shah, Y. M. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00481-16 · Cited by 72
CCL1 is a major regulatory T cell attracting factor in human breast cancer
Kühnemuth, B., Piseddu, I., Wiedemann, G. M., Lauseker, M., Kühn, C., Hofmann, S., Schmoeckel, E., Endres, S., Mayr, D. C., Jeschke, U., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5117-8 · Cited by 91
Treg programming and therapeutic reprogramming in cancer
Ayala, M. A. M., Li, Z., & DuPage, M. J. P. (2019) · Immunology · doi:10.1111/imm.13058 · Cited by 78
Yuan, C.-S., Deng, Z., Qin, D., Mu, Y., Chen, X., & Liu, Y. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.02.030 · Cited by 73
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
“Studies in mesothelioma and other malignancies indicate that both processes are driven by tumor cells, cancer associated fibroblasts, MDSCs, TAMS, and T-regulatory cells (33, 36, 126, 127).”
BackgroundTumor accomplice: T cell exhaustion induced by chronic inflammation
Fang, L., Liu, K., Liu, C., Wang, X., Ma, W., Xu, W., Wu, J., & Sun, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.979116 · Cited by 77
“Treg cells Release immunosuppressive molecules Induce DCs to express immunosuppressive molecules Express cytotoxic T lymphocyte antigen 4 (CTLA4) Produce adenosine, Inhibit tumor-associated antigen presentation, Inhibit cytolytic granule release (114, 117, 118)”
BackgroundGuillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
“In addition, a hypoxic microenvironment induces chemokines favoring the recruitment of regulatory T cells and leading to immunosuppressive angiogenesis.(113,114) At the level of the tumor cell, hypoxia promotes autophagy, which makes the tumor cell resistant to cytotoxic CD8 T cells.”
BackgroundTargeting Hypoxia-Driven Metabolic Reprogramming to Constrain Tumor Progression and Metastasis
Galvis, M. M., & Teng, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155487 · Cited by 76
The abscopal effect in patients with cancer receiving immunotherapy
Nelson, B. E., Adashek, J. J., Lin, S. H., & Subbiah, V. (2023) · Med · doi:10.1016/j.medj.2023.02.003 · Cited by 76
Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis
Mazzone, M., & Bergers, G. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114721 · Cited by 74
“In contrast, regulatory T cells (Tregs) suppress IFN-γ–expressing CD4 Th1 cells and secrete VEGF via hypoxia-induced CCL28, which both contribute to a proangiogenic tumor environment (72).”
BackgroundLam, T., Tsang, K. C., Choi, C., Lee, V. H.-F., Lam, K. O., Chiang, C., So, T. H., Chan, W., Nyaw, S. F., Lim, F., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.004 · Cited by 72
Emerging roles of regulatory T cells in tumour progression and metastasis
Halvorsen, E. C., Mahmoud, S., & Bennewith, K. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9529-x · Cited by 80
“Tregs from murine spleens, secrete VEGF-A and induce endothelial cell accumulation and expansion in vitro [25].”
BackgroundChemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions
Zhang, X., Ding, K., Wang, J., Li, X., & Zhao, P. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.063 · Cited by 73
Regulation of regulatory T cells in cancer
Stockis, J., Roychoudhuri, R., & Halim, T. Y. F. (2019) · Immunology · doi:10.1111/imm.13064 · Cited by 68
Zhou, Z., Xin, H., Li, J., Hu, Z., Luo, C., & Zhou, S. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02355-3 · Cited by 69
Zsíros, E., Duttagupta, P. A., Laniti, D. D., Li, H., Frank, R., Garrabrant, T. A., Hagemann, I. S., Levine, B. L., June, C. H., Zhang, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2777 · Cited by 66
“These data are in agreement with previous observations (2, 27, 28).”
ResultSelf-citationβ 3 ‐Adrenoceptor as a potential immuno‐suppressor agent in melanoma
Calvani, M., Bruno, G., Monte, M. D., Nassini, R., Fontani, F., Casini, A., Cavallini, L., Becatti, M., Bianchini, F., Logu, F. D., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14660 · Cited by 69
“This is intriguing, considering that hypoxia is indicated as one of the most important regulators of cancer immune-tolerance (Facciabene et al., 2011) and supports the hypothesis that β3-ARs might participate, in a hypoxic environment, to the acquisition of an immunetolerant phenotype.”
BackgroundZhang, R., Luo, W., Zhang, Y., Zhu, D., Midgley, A. C., Song, H., Khalique, A., Zhang, H., Zhuang, J., Kong, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz8011 · Cited by 66
Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade5111 · Cited by 65
Differential roles of regulatory T cells in acute respiratory infections
Jovisic, M., Mambetsariev, N., Singer, B. D., & Morales‐Nebreda, L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170505 · Cited by 70
“Facciabene and colleagues reported that hypoxic intraperitoneal tumors upregulate CCL28 to recruit CCR10+ Tregs (104).”
Du, G., Dou, C., Sun, P., Wang, S., Liu, J., & Ma, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431211 · Cited by 74
Kraja, F., Jurišić, V., Hromić-Jahjefendić, A., Rossopoulou, N., Κάτσιλα, Θ., Martinović, K. M., Rivas, J. D. L., Diaconu, C. C., & Szöőr, Á. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601773 · Cited by 76
Kandalaft, L. E., Chiang, C. L.-L., Tanyi, J. L., Motz, G. T., Balint, K., Mick, R., & Coukos, G. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-149 · Cited by 67
“Importantly, Treg cells and VEGF are interconnected; hypoxia (which drives expression of VEGF) induces also accumulation of CCR10 Treg cells in ovarian tumors, while Treg cells can in turn reprogram the tumor microenvironment towards angiogenesis [132].”
BackgroundSelf-citationHoming to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells
Ager, A., Watson, H. A., Wehenkel, S. C., & Mohammed, R. N. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150254 · Cited by 74
“There has been a growing realization that hypoxia also fuels the immunosuppressive tumour microenvironment, in part due to accumulation of immunosuppressive leucocytes such as Foxp3 + regulatory T-cells (Tregs) [48].”
BackgroundTumor-Cell Death, Autophagy, and Immunity
Weiner, L. M., & Lotze, M. T. (2012) · New England Journal of Medicine · doi:10.1056/nejmcibr1114526 · Cited by 69
Fan, K., Yang, C., Fan, Z., Huang, Q., Zhang, Y., Cheng, H., Jin, K., Yu, L., Wang, Z., Luo, G., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.017 · Cited by 69
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Hollow Mesoporous Manganese Oxides: Application in Cancer Diagnosis and Therapy
Xu, W., Qing, X., Liu, S., Yang, D., Dong, X., & Zhang, Y. (2022) · Small · doi:10.1002/smll.202106511 · Cited by 69
Wang, W., Li, X., Ding, X., Xiong, S., Hu, Z.-L., Lu, X., Zhang, K., Zhang, H., Hu, Q., Lai, K. S., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.019 · Cited by 72
Mortezaee, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117145 · Cited by 65
Xing, X., Shi, J., Jia, Y., Dou, Y., Li, Z., Dong, B., Guo, T., Cheng, X., Li, X., Du, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003984 · Cited by 72
Zhang, L., Takara, K., Yamakawa, D., Kidoya, H., & Takakura, N. (2015) · Cancer Science · doi:10.1111/cas.12836 · Cited by 68
Self-citationMayer, A., & Vaupel, P. W. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-7411-1_28 · Cited by 75
Sahu, A., Köse, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., Santella, A., Alfonso, A., Li, M., Cordova, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32738-7 · Cited by 73
Tissue resident regulatory T cells: novel therapeutic targets for human disease
Zhou, X., Tang, J., Cao, H., Fan, H., & Li, B. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.23 · Cited by 72
Chen, Z., Kim, S.-J., Essani, A. B., Volin, M. V., Vila, O. M., Swedler, W. I., Arami, S., Volkov, S., Sardin, L. V., Sweiss, N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204530 · Cited by 62
Targeting roles of inflammatory microenvironment in lung cancer and metastasis
Shi, L., Wang, L., Hou, J., Zhu, B., Min, Z., Zhang, M., Song, D., Cheng, Y., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9570-4 · Cited by 62
“of new blood vessels within tumor-progressing microenvironment [54] and in the recruitment of immunosuppressive T reg-”
BackgroundSelf-citationHypoxia-inducible factors as key regulators of tumor inflammation
Mamlouk, S., & Wielockx, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.27901 · Cited by 61
“They demonstrated that HIF1a promotes angiogenesis and tolerance via recruitment of CCL28-induced CXCR10-expressing T-cells.(102) The work of this group highlights the connection between immune tolerance displayed in the tumor environment and angiogenesis.”
BackgroundTumor-infiltrating regulatory T cells: origins and features.
Deng, G. (2018) · Europe PMC (PubMed Central) · Cited by 76
Tang, T., Huang, X., Lu, M., Zhang, G., Han, X., & Liang, T. (2023) · Nature Communications · doi:10.1038/s41467-023-38578-3 · Cited by 68
Targeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 77
Liu, X., Jin, H., Zhang, G., Lin, X., Chen, C., Sun, J., Zhang, Y., Zhang, Q., & Yu, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106834 · Cited by 66
“It has been reported that Tregs recruitment had a key role in establishing a VEGF-rich tumor microenvironment and increasing tumor angiogenesis [41].”
BackgroundControl of the Antitumor Immune Response by Cancer Metabolism
Domblides, C., Lartigue, L., & Faustin, B. (2019) · Cells · doi:10.3390/cells8020104 · Cited by 68
“Hypoxic tumor cells enhance Treg recruitment, through the production of CCL28 which interacts with CXCR10 (a proangiogenic and immunosuppressive molecule) [210], the expression of neuropilin-1 (NP-1) which attracts Tregs in response to VEGF [211], or the secretion of the chemoattractant TGF-β by tumor cells [212].”
Eckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
“Another major mechanism described for ovarian as well as for liver cancer is the induction of CCL28.”
BackgroundJiang, Z., Hsu, J. L., Li, Y., Hortobágyi, G. N., & Hung, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01197 · Cited by 67
“Other hypoxia-induced molecules, such as, CCL28, recruit CC chemokine receptor 10-positive Tregs to the tumor region and facilitate tumor immune evasion (61).”
Background3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy
Zhu, Y., Kang, E., Wilson, M., Basso, T., Chen, E., Yu, Y., & Li, Y.-R. (2022) · Organoids · doi:10.3390/organoids1020012 · Cited by 67
Regulatory T cells turn pathogenic
Guo, J., & Zhou, X. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.12 · Cited by 63
Huang, G., Tao, L., Shen, S., & Chen, L. (2016) · Scientific Reports · doi:10.1038/srep27152 · Cited by 63
Crispin‐Ortuzar, M., Apte, A., Grkovski, M., Oh, J. H., Lee, N. Y., Schöder, H. M., Humm, J. L., & Deasy, J. O. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.11.025 · Cited by 67
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Xie, G., Tan, C., Lin, J., Zhang, L., Zheng, J., Liu, Y., Xie, G., Wang, B., & Yuan, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0401-3 · Cited by 65
“CCL28 Recruiting Tregs in tumor hypoxia microenvironment [62].”
BackgroundSelf-citationEngineering chimeric antigen receptor T cells for solid tumour therapy
Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 62
Mn( iii )-mediated carbon-centered radicals generate an enhanced immunotherapeutic effect
Li, J., Hu, B., Chen, Z., Li, J., Jin, W., Wang, Y., Wan, Y., Lv, Y., Pei, Y., Liu, H., et al. (2024) · Chemical Science · doi:10.1039/d3sc03635a · Cited by 62
Association of increased Treg and Th17 with pathogenesis of moyamoya disease
Weng, L., Cao, X., Han, L., Zhao, H., Qiu, S., Yan, Y., Wang, X., Chen, X., Zheng, W., Xu, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03278-8 · Cited by 59
Lei, J., Wang, H., Zhu, D., Wan, Y., & Yin, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29358 · Cited by 59
“…derived suppressor cells, M2 tumor‐ associated macrophages, and regulatory T cells that promote the immunosuppression and limit the killing functions of cytotoxic T lymphocytes (CTL; Brand et al., 2016; Facciabene et al., 2011; Laoui et al., 2014; Scott & Cleveland, 2016; Tang et al., 2012).”
BackgroundAhlmanner, F., Sundström, P., Akéus, P., Eklöf, J., Börjesson, L., Gustavsson, B. G., Lindskog, E. B., Raghavan, S., & Quiding‐Järbrink, M. (2018) · Oncotarget · doi:10.18632/oncotarget.26435 · Cited by 63
“However, CCL28 production in CRC tissue is low [37], which may explain the lower migration Oncotarget37002www.oncotarget.com of CCR10-expressing Treg to the tumors.”
BackgroundTumors resurrect an embryonic vascular program to escape immunity
Huijbers, E. J. M., Khan, K. A., Kerbel, R. S., & Griffioen, A. W. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm6388 · Cited by 64
“Other effects of VEGF-A include the induction of an abnormal vasculature leading to hypoxia and resulting in various immunosuppressive features (36).”
BackgroundSjöberg, E., Melssen, M. M., Richards, M., Ding, Y., Chanoca, C., Chen, D., Nwadozi, E., Pal, S., Love, D. T., Ninchoji, T., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci161366 · Cited by 63
“Thus, increased hypoxia promotes the expansion of Tregs and drives T cell exhaustion, promotes polarization of tumor promoting macrophages (TAMs), and accumulation of myeloid-derived suppressor cells (6, 62, 63).”
BackgroundCAR T‐cell immunotherapy: The path from the by‐road to the freeway?
Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 64
“This may be achieved by hypoxia-driven production of cytokines and chemokines such as transforming growth factor (TGF)-b and CCL28 by tumour cells (Facciabene et al., 2011; Hasmim et al., 2013).”
BackgroundShibahara, I., Saito, R., Zhang, R., Chonan, M., Shoji, T., Kanamori, M., Sonoda, Y., Kumabe, T., Kanehira, M., Kikuchi, T., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0307-3 · Cited by 58
“Moreover, ovarian cancer produced CC-chemokine ligand 28 under hypoxic conditions, resulting in Treg cell recruitment and the induction of tumor angiogenesis through VEGFA secretion [34].”
CCL22 Signaling in the Tumor Environment
Röhrle, N., Knott, M. M. L., & Anz, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36667-4_8 · Cited by 72
Tumor Endothelial Cell–Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway
Taguchi, K., Onoe, T., Yoshida, T., Yamashita, Y., Tanaka, Y., & Ohdan, H. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0897 · Cited by 62
“For instance, hypoxia, which is known to drive angiogenesis in tumors, also promotes immune tolerance (55).”
BackgroundTumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
Russo, E., Santoni, A., & Bernardini, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0320-205r · Cited by 60
The outstanding antitumor capacity of CD4+ T helper lymphocytes
Li, T., Wu, B., Yang, T., Zhang, L., & Jin, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188439 · Cited by 63
Self-citationThe therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
FOXP3+ regulatory T cells and the immune escape in solid tumours
Qiu, Y., Ke, S., Chen, J., Qin, Z., Zhang, W., Yuan, Y., Meng, D., Zhao, G., Wu, K., Li, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982986 · Cited by 70
Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors
Stehle, F., Schulz, K., Fahldieck, C., Kalich, J., Lichtenfels, R., Riemann, D., & Seliger, B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437962 · Cited by 62
“Sunitinib reduced the number of immunosuppressive Tregs more strongly than sorafenib at a concentration of 5 M (Fig.”
BackgroundInfluentialTang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12546 · Cited by 66
“Tumor cells can recruit Tregs by upregulating the expression of C-C motif chemokine ligand 28 (CCL28) to enhance tumor immune tolerance and promote angiogenesis [80].”
BackgroundMaeda, S., Ohno, K., Fujiwara‐Igarashi, A., Uchida, K., & Tsujimoto, H. (2015) · Veterinary Pathology · doi:10.1177/0300985815591081 · Cited by 75
“The chemokines CCL22 and CCL28 promote the migration of Tregs into tumor tissues through their receptors, CCR4 and CCR10, respectively.(12,15,57) Other chemokine CXCR3 ligands, such as CXCL9, CXCL10, and CXCL11, also induce Treg infiltration.”
BackgroundMultispectral Imaging: A Review of Its Technical Aspects and Applications in Anatomic Pathology
Mansfield, J. R. (2013) · Veterinary Pathology · doi:10.1177/0300985813506918 · Cited by 67
Jamieson, S. M. F., Tsai, P., Kondratyev, M. K., Budhani, P., Liu, A. J., Senzer, N. N., Chiorean, E. G., Jalal, S. I., Nemunaitis, J. J., Kee, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122204 · Cited by 62
Molecular-targeted therapies and precision medicine for endometrial cancer
Mitamura, T., Dong, P., Ihira, K., 工藤, 正., & Watari, H. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy159 · Cited by 59
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 60
“…CCL22, and CCL28, which attract myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs), the two major immunosuppressive cells neutralizing the cytotoxicity of effector T cells in solid tumors (Gobert et al., 2009; Facciabene et al., 2011; Hillerdal and Essand, 2015) (Figure 2D).”
BackgroundInducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Xie, M., Wei, J., & Xu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00676 · Cited by 60
“Reportedly, interactions between CXCL12 and CXCR4 (111), CCL20 and CCR6 (112), CCL18 and CCR8 (113, 114), CXCL1 and CXCR2 (115), and CCL28 and CCR10 (116, 117) are also important contributors to Treg accumulation in NSCLC.”
BackgroundChang, W. H., & Lai, A. G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.011 · Cited by 55
Programming the lifestyles of engineered bacteria for cancer therapy
Fu, S., Zhang, R., Gao, Y., Xiong, J., Li, Y., Pu, L., Xia, A., & Jin, F. (2023) · National Science Review · doi:10.1093/nsr/nwad031 · Cited by 64
“The hypoxia and immune-privileged tumor microenvironment is one of the biggest obstacles in the way of many cancer therapeutics [1–3], such as chemotherapy [4], radiotherapy [5] and immunotherapy [6,7].”
BackgroundYu, H., Li, J., Peng, S., Liu, Q., Chen, D., He, Z., Xiang, J., & Wang, B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217385 · Cited by 69
Tumour hypoxia in driving genomic instability and tumour evolution
Suvac, A., Ashton, J., & Bristow, R. G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00781-9 · Cited by 142
Oxidation-responsive Eu 2+/3+ -liposomal contrast agent for dual-mode magnetic resonance imaging
Ekanger, L. A., Ali, M. M., & Allen, M. J. (2014) · Chemical Communications · doi:10.1039/c4cc07027e · Cited by 60
AGR2 Expression is Regulated by HIF-1 and Contributes to Growth and Angiogenesis of Glioblastoma
Hong, X., Wang, J., & Li, Z. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9650-4 · Cited by 55
CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion
Park, J., Zhang, X., Lee, S., Song, N., Son, S. H., Kim, K., Shim, J. H., Park, K.-K., & Chung, W. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125336 · Cited by 56
Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target
Hashemi, V., Maleki, L. A., Esmaily, M., Masjedi, A., Ghalamfarsa, G., Namdar, A., Yousefi, M., Yousefi, B., & Jadidi‐Niaragh, F. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106087 · Cited by 61
Treg specialization and functions beyond immune suppression
Astarita, J. L., Dominguez, C. X., Tan, C., Guillen, J., Pauli, M. L., Labastida, R., Valle, J., Kleinschek, M. A., Lyons, J., & Zarrin, A. A. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac123 · Cited by 60
“Initial data pointed only to correlations between increased Treg numbers, vascular endothelial growth factor (VEGF) expression, and angiogenesis in tumors [68], but follow-up work has identified Tregs as a direct producer of VEGF and modulator of angiogenesis [69].”
Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy
Mpekris, F., Panagi, M., Charalambous, A., Voutouri, C., & Stylianopoulos, T. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101626 · Cited by 78
“49 MDSCs are a heterogeneous population of immature myeloid cells that are recruited to the TME to suppress host immunity 46 and promote the proliferation of Tregs in a TGF-b -dependent manner.”
Suzuki, K., Sentani, K., Tanaka, H., Yano, T., Suzuki, K., Oshima, M., Yasui, W., Tamura, A., & Tsukita, S. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.03.003 · Cited by 55
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
Mossenta, M., Busato, D., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Cancers · doi:10.3390/cancers11081086 · Cited by 56
Signaling in and out: long-noncoding RNAs in tumor hypoxia
Kuo, T.-C., Kung, H.-J., & Shih, J.-W. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00654-x · Cited by 56
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Fucikova, J. P., Coosemans, A., Oršulić, S., Cibula, D., Vergote, I. B., Galluzzi, L., & Špíšek, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002873 · Cited by 62
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 56
“First, tumor hypoxia induces the upregulation of chemokine ligands CCL-22 and CCL-28, which preferentially recruit Tregs into tumors (73, 74).”
BackgroundFunctional dynamics of Foxp3+ regulatory T cells in mice and humans
Dhuban, K. B., Kornete, M., Mason, E. S., & Piccirillo, C. A. (2014) · Immunological Reviews · doi:10.1111/imr.12168 · Cited by 60
“Increased numbers of Foxp3 Treg cells expressing CCR10 accumulate in CCL28 tumors, which exhibit increased growth and angiogenesis compared with CCL28 / tumors (88).”
Background
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.